EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

19 June 2014
EMA/CAT/378521/2014
Procedure Management and Business Support Division

Committee for Advanced Therapies (CAT)

Minutes of the 15 – 16 May 2014 meeting

Chair: Paula Salmikangas, Vice-chair: Martina Schüßler-Lenz

Declaration on conflict of interest

In accordance with the Agency's revised Policy and Procedure on the handling of conflicts of interests, participants in this meeting were asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests). No additional conflicts of interest were declared.
Discussions, deliberations and voting took place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee Secretariat at the start of meeting. The discussion, deliberations and voting took place in the presence of 22 CAT members (quorum reached).

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regards to therapeutic indications listed against products, it must be noted that these may not reflect the full wording proposed by the applicant and may also vary during the course of the review. The procedures discussed at CAT are on-going and therefore certain aspects are considered confidential. Additional details on some of the procedures (for example the ATMP classification procedure) will be published in the CAT monthly report. For orphan medicinal products the product name and the applicant are published to be consistent with already publicly available information. Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes. Further information with relevant explanatory notes can be found at the end of this document.

Note on access to documents

Some documents mentioned in the agenda/minutes cannot be released at present following a request for access to documents under Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7051
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

1. PLENARY RELATED DOCUMENTS

1.1. AGENDA (EMA/CAT/58386/2014) and **TIMESCHEDULE** (EMA/CAT/263808/2014) for the CAT plenary to be held on 15th and 16th May 2014: **for adoption**	Adopted
1.2. TABLE OF DECISIONS CAT plenary held on 15th and 16th April 2014 (EMA/CAT/738659/2014): **for information**	Noted
1.3. MINUTES of the CAT plenary held on 15th and 16th April 2014 (EMA/CAT/261860/2014): **for adoption**	Adopted
1.4. PRE-MEETING LIST of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session of 15th – 16th May 2014: **for information**	*See May minutes (to be published post June 2014 CAT meeting)*

2. EVALUATION OF ATMPS

2.1. OPINION
No items on the agenda

2.2. ORAL EXPLANATION
No items on the agenda

2.3. LIST OF QUESTIONS
No items on the agenda

2.4. DAY 80 ASSESSMENT REPORT
No items on the agenda

2.5. RE-EXAMINATION PROCEDURE (NEW APPLICATIONS)+UNDER ARTICLE 9(2) OF REGULATION No 726/2004
No items on the agenda

2.6. WITHDRAWAL OF APPLICATION
No items on the agenda

2.7. ONGOING EVALUATION PROCEDURES
No items on the agenda

2.8. NEW APPLICATIONS
No items on the agenda

2.9. GMP and GCP INSPECTIONS REQUESTS
No items on the agenda

2.10. POST-AUTHORISATION

2.10.1. Type II Variations

2.10.1.1. Glybera (EMEA/H/C/002145) MAH: UniQure Biopharma B.V. *Orphan* **II/34** **Scope:** submission of final study report AMT011-02 **For adoption:** ▪ Timetable	CAT Rapporteur: E. French (UK) CHMP Co-ordinator: G. Markey (UK) CAT was informed that the start of this procedure was postponed due to the missing information.

2.10.1.2. Glybera (EMEA/H/C/002145) MAH: UniQure Biopharma B.V. *Orphan* **II/33** **Scope:** Quality. **For adoption:** ▪ Timetable	CAT Rapporteur: E. French (UK) CHMP Co-ordinator: G. Markey (UK) The evaluation timetable was adopted.

2.10.2. Other PA Activities

2.10.2.1. Glybera (EMEA/H/C/002145) MAH: UniQure Biopharma B.V. *Orphan* **For discussion/opinion:** ▪ Updated assessment report from the rapporteur following CAT members' comments	CAT Rapporteur: E. French (UK) CHMP Co-ordinator: G. Markey (UK) CAT discussed the updated report from the rapporteur. CAT decided to invite the company for an oral explanation during the June meeting in the framework of the finalisation of variation II/30 (Update of protocol of the CM efficacy and safety study requested in Annex II).
2.10.2.2. ChondroCelect (characterised viable autologous cartilage cells expanded *ex vivo* expressing specific marker proteins) (EMA/H/C/00878). MAH: TiGenix N.V. **Scope:** Five-year renewal **For adoption:** ▪ Draft opinion ▪ CAT draft AR	CAT Rapporteur: E. Flory (DE) CHMP Co-ordinator: J. Müller-Berghaus (DE) CAT adopted a second request for supplementary information.

3. CERTIFICATION

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4. SCIENTIFIC RECOMMENDATION ON CLASSIFICATION OF ATMPs

4.1. [characterised viable autologous stem cells expanded in vitro]. Proposed indication: treatment of degenerative arthritis, osteoarthritis (OA), articular cartilage defects in the knee, ankle or hip joints. **For information:** ▪ ATMP Classification report	See also 7.3. *The European Commission raised no comments.* *Noted*

4.2.	[autologous collagen type II-specific regulatory Treg lymphocyte expanded population]. Proposed indication: treatment of inflammatory eyes diseases and inflammatory articular diseases **For information:** ▪ ATMP Classification report	*The European Commission raised no comments.* *Noted*
4.3.	[polyethylene terephthalate (PET) scaffold seeded with autologous bone marrow derived mononuclear cell]. Proposed indication: reconstruction of trachea subsequent to damage or stenosis due to cancer, injury or infection. **For information:** ▪ ATMP Classification report	An ITF Briefing meeting took place in November 2013. *The European Commission raised no comments.* *Noted*
4.4.	[Concentrate of autologous, uncultured, custom prepared bone marrow aspirate]. Proposed indication: field of regenerative medicine: bone damaged by disease (e.g. ostenecrosis), fracture or age-related loss of bone function. **For adoption:** ▪ ATMP Classification report	The CAT discussed the ATMP classification report and considered that this product should be classified as a , based on non-homologous use of the bone marrow concentrate in this indication. The updated ATMP classification report will be circulated to the CAT members on Monday for adoption via written procedure until Wednesday 21 May 2014. CAT secretariat to send the draft scientific recommendation to the Commission for comments until 13 June 2014 The CAT recommendation will be considered final if no comments are received from the Commission. The final report will be sent thereafter to the Applicant.
4.5.	[an antiinfectious naked DNA vaccine encoding mutationinactivated E7-E6 fusion protein from Human Papillomavirus 16 linked to the human chemokine hMIP-1α via a dimerization module derived from human IgG3.]. Proposed indication: to prevent and treat HPV16 induced pre-malignancies and malignancies. **For adoption:** ▪ ATMP Classification report	CAT agreed on the question to be asked to the applicant before finalisation of the ATMP classification request CAT considered that the reflection paper on ATMP classification, which is currently revised, should address the above situation (GTMP vs vaccine against infectious disease).

4.6.	[active substance (NTC8685-eRNA41H-Ubi-hTERT) is a double-stranded naked DNA plasmid of 7120 bp encoding an inactive human telomerase reverse transcriptase protein fused to ubiquitin (Ubi-hTERT)]. Proposed indication: immunotherapy (therapeutic DNA vaccination) for the treatment of various malignancies and the prevention of tumour relapse. **For information:** ▪ Request received on 15th April 2014 **For adoption:** ▪ Appointment of CAT Co-ordinator ▪ Timetable	Nominations were received from: The following CAT member was appointed as the CAT co-ordinator:
4.7.	[an oncolytic virus derived from type 1 herpes simplex virus (HSV-1) by deletion of two genes (ribonucleotid reductase RR/ICP6, and gamma34.5) and re-insertion of one copy of gamma34.5 gene under expression control of b-myb transcription factor inserted upstream]. Proposed indication: treatment of advanced pancreatic cancer and / or unresectable hepatocellular carcinoma **For information:** ▪ Request received on 29th April 2014 **For adoption:** ▪ Appointment of CAT Co-ordinator ▪ Timetable	Nominations were received from: The following CAT member was appointed as the CAT co-ordinator:
4.8.	[ex-vivo cultured adult human (mononuclear) apoptotic cells]. Proposed indication: prevention of graft versus host disease. **For information:** ▪ Request received on 1st May 2014 **For adoption:** ▪ Appointment of CAT Co-ordinator ▪ Timetable	Nominations were received from: The following CAT member was appointed as the CAT co-ordinator:
4.9.	Reflection paper on classification of ATMPs: **for adoption for external consultation**	The adoption was postponed to allow the drafting group to refine the guidance on the demarcation between gene therapy products and vaccines against an infectious disease.

5. SCIENTIFIC ADVICE

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6. PRE-AUTHORISATION ACTIVITIES

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric Investigation Plan (PIP)

No items on the agenda

7. ITF BRIEFING MEETINGS IN THE FIELD OF ATMPs

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

8. ORGANISATIONAL MATTERS

8.1. Regulatory and Procedural Guidance

8.1.1. Legislation on tissues and cells: legislative proposals on importation of tissues and cells and on coding system for each donation: **for discussion**	Initial discussion took place in March 2014 CAT discussed possible consequences of both legal proposal for tissue and cells for the ATMP manufacturers. The CAT feedback will be sent to the Commission for their consideration.
8.1.2. Adaptive licensing pilot project **For agreement:** ▪ CAT members joining the ALDG	Note: Further to the changes in CAT composition and election of new CAT chair and vice chair, CAT is asked to agree with following new members joining the ALDG: Martina Schüßler-Lenz, Olli Tenhunen (second SAWP-CAT member). Following CAT members remain member of ALDG: P. Salmikangas, H. Ovelgönne.
8.1.3. Report from the European Commission to the European Parliament and the Council on the application of the ATMP Regulation: **for information**	Report published on the EC website on 1st April 2014 http://ec.europa.eu/health/files/advtherapies/2014_atmp/atmp_en.pdf The decision to review the ATMP regulation will only be taken when the new Commission is in place.

8.2. CAT Meeting Organisation

8.2.1. Call for interest for one CAT member with clinical background to join the SAWP **For agreement:** ▪ Recommendation of CAT member to join the SAWP	CAT agreed with the nomination of Olli Tenhunen as the second SAWP-CAT member.
8.2.2. CAT Membership **For information:** ▪ Latvia: Una Riekstina – new member nominated on 22nd April 2014	Noted. Zsuszana Buzas (Hungary) announced that this will be her last CAT meeting before retirement. The CAT chair thanked her for her contributions to the CAT.

8.2.3. CAT-Meeting Management Documents (MMD) **For information:** ▪ MMD useful tips for delegates ▪ Streamlined architecture	The presentation with useful tips was noted. CAT members proposed to remove the subfolders in MMD 02-Evaluation and replace them by the names of the ATMPs on the agenda.

8.3. Co-ordination with Committees/WPs/SAGs

8.3.1. CHMP April 2014 ToD: **for information**	Noted
8.3.2. COMP May 2014 agenda: **for information**	Noted
8.3.3. Draft agenda of the EMA Human Scientific Committees' Working Parties with Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals' Organisations (HCPWP) joint meeting (3 June 2014): **for information**	Noted

8.4. CAT's Work Programme

8.4.1. WP's objectives 2014-2015 **For agreement on objectives for 2014:** ▪ Appointment of Organising/programme committee members for: 2) Assessor training 3) Interested parties meeting ▪ Discussion of scientific topics identified for horizon scanning ▪ Appointment of CAT member(s) to analyse and review of existing guidelines	CAT agree on the following: - to postpone the assessor training to the first half of 2015 - to organise an interested parties meeting in the margins of the October or November 2014 CAT meeting. Possible topics for discussion: ATMP classification, Risk based Approach. Following CAT members will take part in the organisation of this meeting: Egbert Flory, Martina Schüßler-Lenz, Paula Salmikangas. Additional CAT members willing the join the organising committee should inform the CAT secretariat by 2 June 2014.

9. CAT's DGs / PCWP and HCPWP

9.1. DG on GTMP Guidelines

9.1.1. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products: **for adoption**	The revised guideline was presented. CAT members were asked to provided comments by 02 June 2014. In parallel, the concerned working parties and the guideline consistency group will be consulted. CAT adoption for external consultation will take place on 20.06.14.

9.2. DG on CTMP and TEP Guidelines

9.2.1. CAT workshop on Cell based therapies for Cardiac Repair scheduled for 14th-15th May 2014 **For information:** ▪ Agenda ▪ Oral debriefing	Moderators: Oral feedback was provided by the moderators of the different session. A report and scientific publication will be prepared with the help of the speakers, moderators and the organising committee. CAT agreed that those people could author the article.

10.OTHER SCIENTIFIC TOPICS

10.1. Regulation Forum Gene Therapy discussion Group (RFGTDG) **For information:** ▪ Agenda of the international telecom which took place on 30th April 2014	Postponed until the June CAT meeting. CAT members were informed that all documents related to CAT international interactions are include in folder 'General' in CAT MMD.
10.2. The Committee on Bioethics (DH-BIO) of the Council of Europe's. **For review by the CAT:** ▪ Working document: *'Working document on research on biological materials of human origin'*	The DH-BIO is particularly interested in receiving comments on the following issues: ▪ Storage for future research of residual biological materials (Article 13) ▪ Removal storage and use of biological materials from persons not able to consent (articles 12,14 and 17, paragraph 4) ▪ Governance (Articles 20-24) An initial discussion took place. CAT members were encouraged to send their comments on the document by 30 May 2014 to:

10.3. International Standardization Organisation and Identification of Medicinal Products. (ISO/IDMP EU). Re-activation and extension of a task force to develop the technical specifications describing implementation guides of data elements & structures. **For agreement:** ▪ Recommendation of CAT member to join the task force	CAT agreed with the nomination

11.A.O.B.

11.1. Project 2014: move to 30, Churchill Place, Canary Wharf **For information:** ▪ Updated presentation	CAT noted the information provided.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CAT agenda and should be read in conjunction with the agenda or the minutes.

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (*section 2.9*) and Post-authorisation activities (*section 2.10*).

New applications (*sections 2.1 to 2.9*)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (*section 2.2*)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (*section 2.5*)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (*section 2.6*)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (*section 2.8*)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Inspections Issues (*section 2.9*)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (*section 2.10*)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

ATMP Certification (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs (Section 7)

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Organisational matters (section 8)

This section includes topics related to Regulatory and Procedural Guidance, CAT meeting organisation (including CAT membership) and Co-ordination with other Committees, Working Parties, Scientific Advisory Groups and other groups.

CAT's DGs / PCWP and HCPWP (section 9)

This section refers to the activities of the CAT drafting groups developing Scientific Guidelines for gene therapy medicinal products and for cell-based medicinal products, the EMA/CAT-Notified Body Collaboration Group, the Patient and Consumer Working Party (PCWP) and the Healthcare Professionals Working Party (HCPWP).

Other Scientific Topics (section 10)

This section includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

List of participants: ***including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 15-16 May 2014 meeeting.***

CAT Member	Country	Declaration of interest date	Risk level	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/ substance	Agend a point	Comments
Paula Salmikangas	CAT chair	07/05/2014	1	Full involvement			
Claire Beuneu	Belgium	14/06/2013	1	Full involvement			
Sandra Tomljenovic	Croatia	30/08/2013	1	Full involvement			
Sinan B. Sarac	Denmark	26/03/2014	3	No restrictions			
Nicolas Ferry	France	21/08/2013	1	Full involvement			Attended Thursday 14th
Martina Schüssler-Lenz	Germany	30/04/2014	1	Full involvement			
Zsuzsanna Buzás	Hungary	18/06/2013	1	Full involvement			
Maura O'Donovan	Ireland	30/09/2013	1	Full involvement			Attended Thursday 14th
Paolo Gasparini	Italy	18/09/2013	1	Full involvement			
Una Riekstina	Latvia		1	Full involvement			
Romaldas Mačiulaitis	Lithuania	09/07/2013	2	No restrictions			
Johannes H. Ovelgönne	Netherlands	21/06/2013	1	Full involvement			
Marit Hystad	Norway	13/06/2013	1	Full involvement			
Dariusz Śladowski	Poland	06/08/2013	3	No restrictions			
Simona Badoi	Romania	01/08/2013	1	Full involvement			
Mikuláš Hrubiško	Slovakia	03/07/2013	2	No restrictions			
Metoda Lipnik-	Slovenia	21/06/2013	1	Full involvemen			

CAT Member	Country	Declaration of interest date	Risk level	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/ substance	Agenda point	Comments
Stangelj				t			
Sol Ruíz	Spain	11/06/2013	1	Full involvement			Attended Thursday 14th
Lennart Åkerblom	Sweden	05/06/2013	1	Full involvement			
Elaine French	UK	13/01/2014	1	Full involvement			
Bernd Gänsbacher	IEOT	01/08/2013	1	Full involvement			

CAT Alternate	Country	Declaration of interest date	Risk level	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/ substance	Agenda points	Comments
Egbert Flory	Germany	12/07/2013	1	Full involvement			
Angeliki Roboti	Greece	01/10/2013	1	Full involvement			
Anthony Samuel	Malta	09/05/2014	1	Full involvement			
Rune Kjeken	Norway	27/06/2013	2	No restrictions			Attended Thursday 14th
Margarida Menezes-Ferreira	Portugal	21/06/2013	1	Full involvement			
Ján Kyselovič	Slovakia	04/07/2013	1	Full involvement			
Marcos Timón	Spain	06/05/2014	1	Full involvement			
Björn Carlsson	Sweden	24/06/13	1	Full involvement			

CAT members and alternates by phone	Country	Declaration of interest date	Risk level	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/ substance	Agenda point	Comments
Olli Tenhunen	Finland	14/02/2014	2	Full involvement		5.9. Alecsat 5.10. ERC167 1	

EUROPEAN COMMISSION	Outcome restriction following evaluation of e-DoI for the meeting		Topics on the current Committee Agenda for which restriction applies Product/ substance
Rocío Salvador-Roldán		Full involvement	

CAT Expert *	Country	Declaration of interest date	Risk level	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/ substance	Agenda point	Comments
* Experts were only evaluated against the product they have been invited to talk about.							
Guido Panté	Italy	22/01/2014	3	No restrictions			

CAT Expert by phone*	Country	Declaration of interest date	Risk level	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/ substance	Agenda point
Jean-Hugues Trouvin	France	30/05/2013	1	Full involvement		
Alessandro Aiuti	Italy	30/01/2014	2	No restrictions		9.1.1. Gene Therapy parental guideline
Yuan Zhao	UK	21/04/2014	2	No restrictions		9.1.1. Gene Therapy parental guideline
Christiane Niederlander	UK	27/06/2013	2	No restrictions		9.1.1. Gene Therapy parental guideline

CAT Expert by phone*	Country	Declaration of interest date	Risk level	Outcome restriction following evaluation of e-DoI for the meeting	Topics on the current Committee Agenda for which restriction applies Product/ substance	Agenda point
Matthias Renner	Germany	02/07/2013	3	No restrictions		9.1.1. Gene Therapy parental guideline
Bettina Klug	Germany	26/06/2013	1	Full involvement		9.1.1. Gene Therapy parental guideline